Recent blog posts
Plexium has begun administering PLX-4545, its targeted IKZF2 transcription factor degrader, in a first-stage clinical trial
Latest Hotspot
3 min read
Plexium has begun administering PLX-4545, its targeted IKZF2 transcription factor degrader, in a first-stage clinical trial
21 December 2023
Plexium has begun dosing in a Phase 1 trial for its oral drug PLX-4545, a molecular glue degrader targeting the previously "undruggable" transcription factor IKZF2, also known as Helios.
Read →
The European Commission has approved Blueprint Medicines' AYVAKYT® (avapritinib) as the sole treatment for indolent systemic mastocytosis
Latest Hotspot
3 min read
The European Commission has approved Blueprint Medicines' AYVAKYT® (avapritinib) as the sole treatment for indolent systemic mastocytosis
21 December 2023
The European Commission has sanctioned Blueprint Medicines' drug AYVAKYT® (avapritinib) as the exclusive therapeutic option for indolent systemic mastocytosis.
Read →
Clover Commences Early-Stage Human Testing for Respiratory Syncytial Virus Immunization Prospect
Latest Hotspot
3 min read
Clover Commences Early-Stage Human Testing for Respiratory Syncytial Virus Immunization Prospect
21 December 2023
Clover Biopharmaceuticals, Ltd. has announced the enrollment of the first group of participants for its Phase I clinical trial evaluating the SCB-1019 vaccine against Respiratory Syncytial Virus (RSV).
Read →
The FDA is evaluating the revised NDA for TransCon PTH (Palopegteriparatide) for adult hypoparathyroidism
Latest Hotspot
3 min read
The FDA is evaluating the revised NDA for TransCon PTH (Palopegteriparatide) for adult hypoparathyroidism
21 December 2023
The FDA is reviewing the updated New Drug Application (NDA) for TransCon PTH (also known as Palopegteriparatide) meant for the treatment of hypoparathyroidism in adults.
Read →
Vertex Reports Encouraging Outcomes in Early Trial of New Drug VX-548 for Alleviating Diabetes-Related Nerve Pain
Latest Hotspot
3 min read
Vertex Reports Encouraging Outcomes in Early Trial of New Drug VX-548 for Alleviating Diabetes-Related Nerve Pain
21 December 2023
Vertex Pharmaceuticals Incorporated declared favorable outcomes from its Phase 2 trial assessing various dosages of the targeted NaV1.8 inhibitor, VX-548, in individuals suffering from painful diabetic peripheral neuropathy.
Read →
Wugen Reveals Early Data on WU-CART-007 for Tough Blood Cancers at Annual American Hematology Conference
Latest Hotspot
3 min read
Wugen Reveals Early Data on WU-CART-007 for Tough Blood Cancers at Annual American Hematology Conference
21 December 2023
Wugen Unveils Initial Results from Early-Stage Clinical Assessment of WU-CART-007 in Hard-to-Combat Hematologic Malignancies at the Yearly American Hematology Conference.
Read →
Connect Biopharma reports positive Phase 2b results for Rademikibart in moderate to severe adult asthma
Latest Hotspot
3 min read
Connect Biopharma reports positive Phase 2b results for Rademikibart in moderate to severe adult asthma
21 December 2023
Connect Biopharma has revealed encouraging primary outcomes from its global Phase 2b trial of Rademikibart in treating adults with moderate to severe chronic asthma.
Read →
GigaGen Receives Authorization from FDA to Initiate Phase 1 Study of Cancer Drug GIGA-564 for Solid Tumor Treatment
Latest Hotspot
3 min read
GigaGen Receives Authorization from FDA to Initiate Phase 1 Study of Cancer Drug GIGA-564 for Solid Tumor Treatment
20 December 2023
GigaGen Inc. has announced FDA approval for its IND application. This permits the start of a Phase 1 trial to evaluate GIGA-564's effectiveness in treating diverse solid cancers.
Read →
UNITY Biotechnology Begins Phase 2 ASPIRE Trial Administering UBX1325 to Initial Participants with Diabetic Macular Edema
Latest Hotspot
3 min read
UNITY Biotechnology Begins Phase 2 ASPIRE Trial Administering UBX1325 to Initial Participants with Diabetic Macular Edema
20 December 2023
Biotech company UNITY Biotechnology has launched its Phase 2 ASPIRE trial, administering its aging-focused drug UBX1325 (foselutoclax) to the first patients.
Read →
Mabwell Reveals Regulatory Green Light for Pioneering Nectin-4 Specific Antibody-Drug Conjugate Entering Stage 3 Research Trials
Latest Hotspot
3 min read
Mabwell Reveals Regulatory Green Light for Pioneering Nectin-4 Specific Antibody-Drug Conjugate Entering Stage 3 Research Trials
19 December 2023
Mabwell announced its Phase III trial application for 9MW2821 vs. standard chemo in advanced urothelial carcinoma.
Read →
Hemab Therapeutics has begun dosing the first participant in a Phase 2 trial to evaluate the effectiveness of HMB-001 for Glanzmann's Thrombasthenia
Latest Hotspot
3 min read
Hemab Therapeutics has begun dosing the first participant in a Phase 2 trial to evaluate the effectiveness of HMB-001 for Glanzmann's Thrombasthenia
19 December 2023
Hemab Therapeutics has reported the initial dosing of a participant in a Stage 2 medical trial assessing the efficacy of HMB-001 in addressing Glanzmann's Thrombasthenia.
Read →
NAYA Biosciences publishes new insights on CD38-targeting Flex-NK™ dual-specific antibody in American Society of Hematology journal
Latest Hotspot
3 min read
NAYA Biosciences publishes new insights on CD38-targeting Flex-NK™ dual-specific antibody in American Society of Hematology journal
19 December 2023
NAYA Biosciences Reveals New Findings on Its CD38-Directed Flex-NK™ Dual-Specific Antibody in the Journal Published by the American Society of Hematology.
Read →